U.S. FDA Panel Recommends Sanofi Dengue Vaccine Only For People Ages 9 Up To 17

STAT: Sanofi suffers setback as panel recommends against dengue vaccine in adults
“Sanofi on Thursday suffered a major setback in its bid to market a controversial dengue vaccine in the United States, as a Food and Drug Administration advisory committee recommended against approval for adults. … [T]he advisory panel recommended the agency license the vaccine only for people ages 9 to less than 17…” (Branswell, 3/7).